386 related articles for article (PubMed ID: 31500572)
1. Estimating the impact of a novel drug regimen for treatment of tuberculosis: a modeling analysis of projected patient outcomes and epidemiological considerations.
Kendall EA; Malhotra S; Cook-Scalise S; Denkinger CM; Dowdy DW
BMC Infect Dis; 2019 Sep; 19(1):794. PubMed ID: 31500572
[TBL] [Abstract][Full Text] [Related]
2. Contribution of Pretomanid to Novel Regimens Containing Bedaquiline with either Linezolid or Moxifloxacin and Pyrazinamide in Murine Models of Tuberculosis.
Xu J; Li SY; Almeida DV; Tasneen R; Barnes-Boyle K; Converse PJ; Upton AM; Mdluli K; Fotouhi N; Nuermberger EL
Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30833432
[TBL] [Abstract][Full Text] [Related]
3. Impact and cost-effectiveness of the 6-month BPaLM regimen for rifampicin-resistant tuberculosis in Moldova: A mathematical modeling analysis.
James LP; Klaassen F; Sweeney S; Furin J; Franke MF; Yaesoubi R; Chesov D; Ciobanu N; Codreanu A; Crudu V; Cohen T; Menzies NA
PLoS Med; 2024 May; 21(5):e1004401. PubMed ID: 38701084
[TBL] [Abstract][Full Text] [Related]
4. Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial.
Cevik M; Thompson LC; Upton C; Rolla VC; Malahleha M; Mmbaga B; Ngubane N; Abu Bakar Z; Rassool M; Variava E; Dawson R; Staples S; Lalloo U; Louw C; Conradie F; Eristavi M; Samoilova A; Skornyakov SN; Ntinginya NE; Haraka F; Praygod G; Mayanja-Kizza H; Caoili J; Balanag V; Dalcolmo MP; McHugh T; Hunt R; Solanki P; Bateson A; Crook AM; Fabiane S; Timm J; Sun E; Spigelman M; Sloan DJ; Gillespie SH;
Lancet Infect Dis; 2024 May; ():. PubMed ID: 38768617
[TBL] [Abstract][Full Text] [Related]
5. Incremental Cost Effectiveness of Bedaquiline for the Treatment of Rifampicin-Resistant Tuberculosis in South Africa: Model-Based Analysis.
Schnippel K; Firnhaber C; Conradie F; Ndjeka N; Sinanovic E
Appl Health Econ Health Policy; 2018 Feb; 16(1):43-54. PubMed ID: 28980217
[TBL] [Abstract][Full Text] [Related]
6. Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial.
Tweed CD; Dawson R; Burger DA; Conradie A; Crook AM; Mendel CM; Conradie F; Diacon AH; Ntinginya NE; Everitt DE; Haraka F; Li M; van Niekerk CH; Okwera A; Rassool MS; Reither K; Sebe MA; Staples S; Variava E; Spigelman M
Lancet Respir Med; 2019 Dec; 7(12):1048-1058. PubMed ID: 31732485
[TBL] [Abstract][Full Text] [Related]
7. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis.
Dawson R; Diacon AH; Everitt D; van Niekerk C; Donald PR; Burger DA; Schall R; Spigelman M; Conradie A; Eisenach K; Venter A; Ive P; Page-Shipp L; Variava E; Reither K; Ntinginya NE; Pym A; von Groote-Bidlingmaier F; Mendel CM
Lancet; 2015 May; 385(9979):1738-1747. PubMed ID: 25795076
[TBL] [Abstract][Full Text] [Related]
8. Clinical Impact of Rapid Drug Susceptibility Testing to Accompany Fluoroquinolone-Containing Universal Tuberculosis Regimens: A Markov Model.
Kendall EA; Malhotra S; Cook-Scalise S; Dowdy DW; Denkinger CM
Clin Infect Dis; 2020 Dec; 71(11):2889-2896. PubMed ID: 31813958
[TBL] [Abstract][Full Text] [Related]
9. Value of pyrazinamide for composition of new treatment regimens for multidrug-resistant Mycobacterium tuberculosis in China.
Xia H; van den Hof S; Cobelens F; Zhou Y; Zhao B; Wang S; Zhao Y
BMC Infect Dis; 2020 Jan; 20(1):19. PubMed ID: 31910878
[TBL] [Abstract][Full Text] [Related]
10. Predictive Modeling to Study the Treatment-Shortening Potential of Novel Tuberculosis Drug Regimens, Toward Bundling of Preclinical Data.
Mudde SE; Ayoun Alsoud R; van der Meijden A; Upton AM; Lotlikar MU; Simonsson USH; Bax HI; de Steenwinkel JEM
J Infect Dis; 2022 Jun; 225(11):1876-1885. PubMed ID: 33606880
[TBL] [Abstract][Full Text] [Related]
11. TB Alliance regimen development for multidrug-resistant tuberculosis.
Murray S; Mendel C; Spigelman M
Int J Tuberc Lung Dis; 2016 Dec; 20(12):38-41. PubMed ID: 28240571
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of bedaquiline, pretomanid and linezolid for treatment of extensively drug-resistant tuberculosis in South Africa, Georgia and the Philippines.
Gomez GB; Siapka M; Conradie F; Ndjeka N; Garfin AMC; Lomtadze N; Avaliani Z; Kiria N; Malhotra S; Cook-Scalise S; Juneja S; Everitt D; Spigelman M; Vassall A
BMJ Open; 2021 Dec; 11(12):e051521. PubMed ID: 34862287
[TBL] [Abstract][Full Text] [Related]
13. Underestimated pyrazinamide resistance may compromise outcomes of pyrazinamide containing regimens for treatment of drug susceptible and multi-drug-resistant tuberculosis in Tanzania.
Juma SP; Maro A; Pholwat S; Mpagama SG; Gratz J; Liyoyo A; Houpt ER; Kibiki GS; Mmbaga BT; Heysell SK
BMC Infect Dis; 2019 Feb; 19(1):129. PubMed ID: 30732572
[TBL] [Abstract][Full Text] [Related]
14. TB-PRACTECAL: study protocol for a randomised, controlled, open-label, phase II-III trial to evaluate the safety and efficacy of regimens containing bedaquiline and pretomanid for the treatment of adult patients with pulmonary multidrug-resistant tuberculosis.
Berry C; du Cros P; Fielding K; Gajewski S; Kazounis E; McHugh TD; Merle C; Motta I; Moore DAJ; Nyang'wa BT
Trials; 2022 Jun; 23(1):484. PubMed ID: 35698158
[TBL] [Abstract][Full Text] [Related]
15. Priority-Setting for Novel Drug Regimens to Treat Tuberculosis: An Epidemiologic Model.
Kendall EA; Shrestha S; Cohen T; Nuermberger E; Dooley KE; Gonzalez-Angulo L; Churchyard GJ; Nahid P; Rich ML; Bansbach C; Forissier T; Lienhardt C; Dowdy DW
PLoS Med; 2017 Jan; 14(1):e1002202. PubMed ID: 28045934
[TBL] [Abstract][Full Text] [Related]
16. Availability of drugs for the treatment of multidrug-resistant/rifampicin-resistant tuberculosis in the World Health Organization European Region, October 2023.
Otto-Knapp R; Edwards S; Kuchukhidze G; Kröger S; Häcker B; Bivol S; Yedilbayev A
Euro Surveill; 2024 Apr; 29(17):. PubMed ID: 38666403
[TBL] [Abstract][Full Text] [Related]
17. Superior Efficacy of a TBI-166, Bedaquiline, and Pyrazinamide Combination Regimen in a Murine Model of Tuberculosis.
Ding Y; Zhu H; Fu L; Zhang W; Wang B; Guo S; Chen X; Wang N; Liu H; Lu Y
Antimicrob Agents Chemother; 2022 Sep; 66(9):e0065822. PubMed ID: 35924925
[TBL] [Abstract][Full Text] [Related]
18. Treatment Strategy for Rifampin-Susceptible Tuberculosis.
Paton NI; Cousins C; Suresh C; Burhan E; Chew KL; Dalay VB; Lu Q; Kusmiati T; Balanag VM; Lee SL; Ruslami R; Pokharkar Y; Djaharuddin I; Sugiri JJR; Veto RS; Sekaggya-Wiltshire C; Avihingsanon A; Sarin R; Papineni P; Nunn AJ; Crook AM;
N Engl J Med; 2023 Mar; 388(10):873-887. PubMed ID: 36808186
[TBL] [Abstract][Full Text] [Related]
19. Cost comparison of nine-month treatment regimens with 20-month standardized care for the treatment of rifampicin-resistant/multi-drug resistant tuberculosis in Nigeria.
Bada FO; Blok N; Okpokoro E; Dutt S; Akolo C; Dakum P; Abimiku A
PLoS One; 2020; 15(12):e0241065. PubMed ID: 33259492
[TBL] [Abstract][Full Text] [Related]
20. The cost-effectiveness of a bedaquiline-containing short-course regimen for the treatment of multidrug-resistant tuberculosis in South Africa.
Mpobela Agnarson A; Williams A; Kambili C; Mattson G; Metz L
Expert Rev Anti Infect Ther; 2020 May; 18(5):475-483. PubMed ID: 32186925
[No Abstract] [Full Text] [Related]
[Next] [New Search]